File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: FTY720: A promising agent for treatment of metastatic hepatocellular carcinoma
  • Basic View
  • Metadata View
  • XML View
TitleFTY720: A promising agent for treatment of metastatic hepatocellular carcinoma
 
AuthorsLee, TK2 1
Man, K2 1
Ho, JW2 1
Wang, XH1
Poon, RTP2 1
Xu, Y3
Ng, KT2 1
Chu, AC2 1
Sun, CK2 1
Ng, IO2 1
Sun, HC3
Tang, ZY3
Xu, R2 1
Fan, ST2 1
 
Issue Date2005
 
PublisherAmerican Association for Cancer Research.
 
CitationClinical Cancer Research, 2005, v. 11 n. 23, p. 8458-8466 [How to Cite?]
DOI: http://dx.doi.org/10.1158/1078-0432.CCR-05-0447
 
AbstractPurpose: Recurrence after resection and metastasis are common in hepatocellular carcinoma and are associated with poor prognosis. Therefore, effective treatment is urgently needed for improvement of patients' survival. Previously, we reported that FTY720 has an antimetastatic effect on hepatocellular carcinoma cell line through down-regulation of Rac signaling pathway. This study aims to investigate the in vivo antimetastatic potential of FTY720 in an orthotopic nude mice model using metastatic human hepatocellular carcinoma cell lines MHCC-97L (lower metastatic potential) and MHCC-97H (higher metastatic potential). Experimental Design: The nude mice bearing liver tumors were randomized into a treatment group and a control group, each with 12 mice. FTY720 was administered at a dosage of 5 or 10 mg/kg via i.p. injection after 7 days of tumor inoculation. Thirty-five days later, the mice were sacrificed for record of intrahepatic and pulmonary metastases. Results: After 35 days of FTY720 treatment at the dosages of 5 and 10 mg/kg, all 12 mice in the treatment group were alive and well. FTY720 at the dosages of 5 and 10 mg/kg significantly suppressed the tumor volume and intrahepatic and pulmonary metastases in the metastatic nude mice model. FTY720 suppressed intrahepatic and pulmonary metastases by inhibition of Rac expression, which at least in part down-regulated the vascular endothelial growth factor expression and CD34 staining in a dose-dependent manner. Conclusion: FTY720 is a promising novel therapeutic drug for treatment of hepatocellular carcinoma metastasis. © 2005 American Association for Cancer Research.
 
ISSN1078-0432
2013 Impact Factor: 8.193
2013 SCImago Journal Rankings: 5.150
 
DOIhttp://dx.doi.org/10.1158/1078-0432.CCR-05-0447
 
ISI Accession Number IDWOS:000233701300033
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorLee, TK
 
dc.contributor.authorMan, K
 
dc.contributor.authorHo, JW
 
dc.contributor.authorWang, XH
 
dc.contributor.authorPoon, RTP
 
dc.contributor.authorXu, Y
 
dc.contributor.authorNg, KT
 
dc.contributor.authorChu, AC
 
dc.contributor.authorSun, CK
 
dc.contributor.authorNg, IO
 
dc.contributor.authorSun, HC
 
dc.contributor.authorTang, ZY
 
dc.contributor.authorXu, R
 
dc.contributor.authorFan, ST
 
dc.date.accessioned2010-09-06T09:43:19Z
 
dc.date.available2010-09-06T09:43:19Z
 
dc.date.issued2005
 
dc.description.abstractPurpose: Recurrence after resection and metastasis are common in hepatocellular carcinoma and are associated with poor prognosis. Therefore, effective treatment is urgently needed for improvement of patients' survival. Previously, we reported that FTY720 has an antimetastatic effect on hepatocellular carcinoma cell line through down-regulation of Rac signaling pathway. This study aims to investigate the in vivo antimetastatic potential of FTY720 in an orthotopic nude mice model using metastatic human hepatocellular carcinoma cell lines MHCC-97L (lower metastatic potential) and MHCC-97H (higher metastatic potential). Experimental Design: The nude mice bearing liver tumors were randomized into a treatment group and a control group, each with 12 mice. FTY720 was administered at a dosage of 5 or 10 mg/kg via i.p. injection after 7 days of tumor inoculation. Thirty-five days later, the mice were sacrificed for record of intrahepatic and pulmonary metastases. Results: After 35 days of FTY720 treatment at the dosages of 5 and 10 mg/kg, all 12 mice in the treatment group were alive and well. FTY720 at the dosages of 5 and 10 mg/kg significantly suppressed the tumor volume and intrahepatic and pulmonary metastases in the metastatic nude mice model. FTY720 suppressed intrahepatic and pulmonary metastases by inhibition of Rac expression, which at least in part down-regulated the vascular endothelial growth factor expression and CD34 staining in a dose-dependent manner. Conclusion: FTY720 is a promising novel therapeutic drug for treatment of hepatocellular carcinoma metastasis. © 2005 American Association for Cancer Research.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationClinical Cancer Research, 2005, v. 11 n. 23, p. 8458-8466 [How to Cite?]
DOI: http://dx.doi.org/10.1158/1078-0432.CCR-05-0447
 
dc.identifier.doihttp://dx.doi.org/10.1158/1078-0432.CCR-05-0447
 
dc.identifier.epage8466
 
dc.identifier.hkuros116899
 
dc.identifier.isiWOS:000233701300033
 
dc.identifier.issn1078-0432
2013 Impact Factor: 8.193
2013 SCImago Journal Rankings: 5.150
 
dc.identifier.issue23
 
dc.identifier.openurl
 
dc.identifier.pmid16322309
 
dc.identifier.scopuseid_2-s2.0-28544451354
 
dc.identifier.spage8458
 
dc.identifier.urihttp://hdl.handle.net/10722/88434
 
dc.identifier.volume11
 
dc.languageeng
 
dc.publisherAmerican Association for Cancer Research.
 
dc.publisher.placeUnited States
 
dc.relation.ispartofClinical Cancer Research
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAnimals
 
dc.subject.meshAntigens, CD34 - metabolism
 
dc.subject.meshCarcinoma, Hepatocellular - drug therapy - metabolism - secondary
 
dc.subject.meshDisease Models, Animal
 
dc.subject.meshDown-Regulation
 
dc.subject.meshHumans
 
dc.subject.meshImmunosuppressive Agents - therapeutic use
 
dc.subject.meshLiver Neoplasms, Experimental - drug therapy - metabolism - pathology
 
dc.subject.meshMice
 
dc.subject.meshMice, Nude
 
dc.subject.meshMicrocirculation
 
dc.subject.meshNeovascularization, Pathologic - prevention & control
 
dc.subject.meshPropylene Glycols - therapeutic use
 
dc.subject.meshSphingosine - analogs & derivatives
 
dc.subject.meshTumor Cells, Cultured
 
dc.subject.meshVascular Endothelial Growth Factor A - metabolism
 
dc.subject.meshWound Healing
 
dc.subject.meshrac GTP-Binding Proteins - chemistry - metabolism
 
dc.titleFTY720: A promising agent for treatment of metastatic hepatocellular carcinoma
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Lee, TK</contributor.author>
<contributor.author>Man, K</contributor.author>
<contributor.author>Ho, JW</contributor.author>
<contributor.author>Wang, XH</contributor.author>
<contributor.author>Poon, RTP</contributor.author>
<contributor.author>Xu, Y</contributor.author>
<contributor.author>Ng, KT</contributor.author>
<contributor.author>Chu, AC</contributor.author>
<contributor.author>Sun, CK</contributor.author>
<contributor.author>Ng, IO</contributor.author>
<contributor.author>Sun, HC</contributor.author>
<contributor.author>Tang, ZY</contributor.author>
<contributor.author>Xu, R</contributor.author>
<contributor.author>Fan, ST</contributor.author>
<date.accessioned>2010-09-06T09:43:19Z</date.accessioned>
<date.available>2010-09-06T09:43:19Z</date.available>
<date.issued>2005</date.issued>
<identifier.citation>Clinical Cancer Research, 2005, v. 11 n. 23, p. 8458-8466</identifier.citation>
<identifier.issn>1078-0432</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/88434</identifier.uri>
<description.abstract>Purpose: Recurrence after resection and metastasis are common in hepatocellular carcinoma and are associated with poor prognosis. Therefore, effective treatment is urgently needed for improvement of patients&apos; survival. Previously, we reported that FTY720 has an antimetastatic effect on hepatocellular carcinoma cell line through down-regulation of Rac signaling pathway. This study aims to investigate the in vivo antimetastatic potential of FTY720 in an orthotopic nude mice model using metastatic human hepatocellular carcinoma cell lines MHCC-97L (lower metastatic potential) and MHCC-97H (higher metastatic potential). Experimental Design: The nude mice bearing liver tumors were randomized into a treatment group and a control group, each with 12 mice. FTY720 was administered at a dosage of 5 or 10 mg/kg via i.p. injection after 7 days of tumor inoculation. Thirty-five days later, the mice were sacrificed for record of intrahepatic and pulmonary metastases. Results: After 35 days of FTY720 treatment at the dosages of 5 and 10 mg/kg, all 12 mice in the treatment group were alive and well. FTY720 at the dosages of 5 and 10 mg/kg significantly suppressed the tumor volume and intrahepatic and pulmonary metastases in the metastatic nude mice model. FTY720 suppressed intrahepatic and pulmonary metastases by inhibition of Rac expression, which at least in part down-regulated the vascular endothelial growth factor expression and CD34 staining in a dose-dependent manner. Conclusion: FTY720 is a promising novel therapeutic drug for treatment of hepatocellular carcinoma metastasis. &#169; 2005 American Association for Cancer Research.</description.abstract>
<language>eng</language>
<publisher>American Association for Cancer Research.</publisher>
<relation.ispartof>Clinical Cancer Research</relation.ispartof>
<subject.mesh>Animals</subject.mesh>
<subject.mesh>Antigens, CD34 - metabolism</subject.mesh>
<subject.mesh>Carcinoma, Hepatocellular - drug therapy - metabolism - secondary</subject.mesh>
<subject.mesh>Disease Models, Animal</subject.mesh>
<subject.mesh>Down-Regulation</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Immunosuppressive Agents - therapeutic use</subject.mesh>
<subject.mesh>Liver Neoplasms, Experimental - drug therapy - metabolism - pathology</subject.mesh>
<subject.mesh>Mice</subject.mesh>
<subject.mesh>Mice, Nude</subject.mesh>
<subject.mesh>Microcirculation</subject.mesh>
<subject.mesh>Neovascularization, Pathologic - prevention &amp; control</subject.mesh>
<subject.mesh>Propylene Glycols - therapeutic use</subject.mesh>
<subject.mesh>Sphingosine - analogs &amp; derivatives</subject.mesh>
<subject.mesh>Tumor Cells, Cultured</subject.mesh>
<subject.mesh>Vascular Endothelial Growth Factor A - metabolism</subject.mesh>
<subject.mesh>Wound Healing</subject.mesh>
<subject.mesh>rac GTP-Binding Proteins - chemistry - metabolism</subject.mesh>
<title>FTY720: A promising agent for treatment of metastatic hepatocellular carcinoma</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=1078-0432&amp;volume=11&amp;issue=23&amp;spage=8458&amp;epage=8466&amp;date=2005&amp;atitle=FTY720:+a+promising+agent+for+treatment+of+metastatic+hepatocellular+carcinoma</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1158/1078-0432.CCR-05-0447</identifier.doi>
<identifier.pmid>16322309</identifier.pmid>
<identifier.scopus>eid_2-s2.0-28544451354</identifier.scopus>
<identifier.hkuros>116899</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-28544451354&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>11</identifier.volume>
<identifier.issue>23</identifier.issue>
<identifier.spage>8458</identifier.spage>
<identifier.epage>8466</identifier.epage>
<identifier.isi>WOS:000233701300033</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Centre for the Study of Liver Disease
  3. Fudan University